These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25148385)

  • 1. Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone.
    Alpay K; Farshchian M; Tuomela J; Sandholm J; Aittokallio K; Siljamäki E; Kallio M; Kähäri VM; Hietanen S
    PLoS One; 2014; 9(8):e105526. PubMed ID: 25148385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-ABL tyrosine kinase modulates p53-dependent p21 induction and ensuing cell fate decision in response to DNA damage.
    Udden SM; Morita-Fujimura Y; Satake M; Ikawa S
    Cell Signal; 2014 Feb; 26(2):444-52. PubMed ID: 24177958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1.
    Sims JT; Ganguly SS; Bennett H; Friend JW; Tepe J; Plattner R
    PLoS One; 2013; 8(1):e55509. PubMed ID: 23383209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
    Huang DY; Chao Y; Tai MH; Yu YH; Lin WW
    J Biomed Sci; 2012 Mar; 19(1):35. PubMed ID: 22462553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
    Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S
    Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network.
    Kim SY; Cordeiro MH; Serna VA; Ebbert K; Butler LM; Sinha S; Mills AA; Woodruff TK; Kurita T
    Cell Death Differ; 2013 Aug; 20(8):987-97. PubMed ID: 23598363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Abl mediates angiotensin II-induced apoptosis in podocytes.
    Chen X; Ren Z; Liang W; Zha D; Liu Y; Chen C; Singhal PC; Ding G
    J Mol Histol; 2013 Oct; 44(5):597-608. PubMed ID: 23515840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
    Gwanmesia PM; Romanski A; Schwarz K; Bacic B; Ruthardt M; Ottmann OG
    BMC Cancer; 2009 Feb; 9():53. PubMed ID: 19216789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
    Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells.
    Esparza-López J; Medina-Franco H; Escobar-Arriaga E; León-Rodríguez E; Zentella-Dehesa A; Ibarra-Sánchez MJ
    J Cancer Res Clin Oncol; 2013 Oct; 139(10):1625-35. PubMed ID: 23892407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming resistance to fulvestrant (ICI182,780) by downregulating the c-ABL proto-oncogene in breast cancer.
    Zhao H; Lo YH; Yu L; Wang SC
    Mol Carcinog; 2011 May; 50(5):383-9. PubMed ID: 21480391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
    Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
    Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.
    Bahjat M; de Wilde G; van Dam T; Maas C; Bloedjes T; Bende RJ; van Noesel CJM; Luijks DM; Eldering E; Kersten MJ; Guikema JEJ
    Cell Cycle; 2019 Sep; 18(18):2307-2322. PubMed ID: 31349760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
    Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
    Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-Abl inhibitor imatinib enhances insulin production by β cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2.
    Xia CQ; Zhang P; Li S; Yuan L; Xia T; Xie C; Clare-Salzler MJ
    PLoS One; 2014; 9(5):e97694. PubMed ID: 24835010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
    Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
    J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.
    Hinchcliff M; Huang CC; Ishida W; Fang F; Lee J; Jafari N; Wilkes M; Bhattacharyya S; Leof E; Varga J
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S86-96. PubMed ID: 22691216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.